艾迪药业
(688488)
| 流通市值：64.55亿 | | | 总市值：64.55亿 |
| 流通股本：4.21亿 | | | 总股本：4.21亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 365,854,758.25 | 178,023,123.63 | 719,170,347.67 | 552,400,249.88 |
| 营业收入 | 365,854,758.25 | 178,023,123.63 | 719,170,347.67 | 552,400,249.88 |
| 二、营业总成本 | 334,577,150.84 | 163,507,908 | 687,867,655.52 | 538,614,945.79 |
| 营业成本 | 126,261,848.72 | 57,829,450.25 | 238,818,750.87 | 189,352,749.77 |
| 税金及附加 | 5,243,002.03 | 2,125,339.64 | 11,844,660.68 | 9,369,817.96 |
| 销售费用 | 117,846,096.88 | 64,499,488.47 | 246,076,221.3 | 187,702,249.75 |
| 管理费用 | 44,443,808.56 | 21,609,793.84 | 90,043,921.92 | 76,940,855.93 |
| 研发费用 | 32,843,287.82 | 13,462,511.41 | 87,365,396.34 | 64,999,220.3 |
| 财务费用 | 7,939,106.83 | 3,981,324.39 | 13,718,704.41 | 10,250,052.08 |
| 其中:利息费用 | 8,405,378.93 | 4,205,443.12 | 15,620,774.14 | 11,918,861.89 |
| 其中:利息收入 | 662,576.12 | 317,961.71 | 2,185,494.79 | 1,836,241.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,820,158.49 | 1,262,722.64 | 18,221,056.17 | 8,304,357.2 |
| 加:投资收益 | -356,371.06 | -188,563.24 | -736,346.86 | -319,794.61 |
| 资产处置收益 | 1,350,583.61 | - | 81,281.88 | 77,620.24 |
| 资产减值损失(新) | -140,834.7 | -53,326.75 | -17,011,257.89 | -4,756,058.36 |
| 信用减值损失(新) | -526,894.29 | 630,869.76 | -54,371.6 | -264,719.27 |
| 其他收益 | 13,040,668.3 | 1,971,738.78 | 16,279,553.49 | 11,644,656.42 |
| 四、营业利润 | 40,824,600.78 | 18,138,656.82 | 48,082,607.34 | 28,471,365.71 |
| 加:营业外收入 | 24,929.05 | 20,477.31 | 1,257,149.36 | 1,063,452.27 |
| 减:营业外支出 | 3,817,625.64 | 2,312,790.34 | 24,698,978.93 | 2,911,890.32 |
| 五、利润总额 | 37,031,904.19 | 15,846,343.79 | 24,640,777.77 | 26,622,927.66 |
| 减:所得税费用 | 4,860,940.86 | 1,657,171.08 | 16,557,710.35 | 10,511,059.43 |
| 六、净利润 | 32,170,963.33 | 14,189,172.71 | 8,083,067.42 | 16,111,868.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 32,170,963.33 | 14,189,172.71 | 8,083,067.42 | 16,111,868.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 22,934,073.66 | 7,606,253.11 | -19,532,305.2 | -6,840,499.38 |
| 少数股东损益 | 9,236,889.67 | 6,582,919.6 | 27,615,372.62 | 22,952,367.61 |
| 扣除非经常损益后的净利润 | 20,456,682.62 | 8,573,957.17 | -20,596,636.61 | -18,612,262.57 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.02 | -0.05 | -0.02 |
| (二)稀释每股收益 | 0.05 | 0.02 | -0.05 | -0.02 |
| 九、综合收益总额 | 32,170,963.33 | 14,189,172.71 | 8,083,067.42 | 16,111,868.23 |
| 归属于母公司股东的综合收益总额 | 22,934,073.66 | 7,606,253.11 | -19,532,305.2 | -6,840,499.38 |
| 归属于少数股东的综合收益总额 | 9,236,889.67 | 6,582,919.6 | 27,615,372.62 | 22,952,367.61 |
| 公告日期 | 2026-08-29 | 2026-04-30 | 2026-03-31 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |